Latest Presentations
MP Corporate Presentation
November 1, 2018
MP Q3 Interim Management Statement Presentation
November 1, 2018
Products
Molecular Partners is advancing a growing pipeline of DARPin therapies for the treatment of severe or life-threatening diseases, with an initial focus on oncology and ophthalmology. Its most advanced oncology candidate, MP0250, is for the treatment of solid tumors and hematological malignancies. In ophthalmology, the most advanced candidate is abicipar in wet age-related macular degeneration (wet AMD). It has been licensed to Allergan and is being tested in two phase III trials.
We tailor each DARPin® therapy to target single or multiple disease pathways responsible for serious and complex diseases, all in a single medicine.
